Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsDopamine inhibits mitochondrial motility in hippocampal neuronsEltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian ratsp11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11.Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.S100-annexin complexes--biology of conditional association.The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.p11 and its role in depression and therapeutic responses to antidepressants.Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease.Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.Association between 5-HTTLPR polymorphism and Parkinson's disease: a meta analysis.Antidepressant-like properties of sarizotan in experimental Parkinsonism.The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson's disease.Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT.CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
P2860
Q21129423-CC60A32C-17FF-4AB4-9FC8-87274503613EQ27300818-4EF0B1FC-DB2E-431C-8890-B424BE121881Q27303857-C3B3A320-7DA9-4927-A521-1EE1DE973A19Q30497984-E65E91BE-B451-4A3A-9E99-7E9624958B7CQ30833645-0C78319A-8EE6-4E48-91A3-1CF96C3F52CFQ35324977-5AB6F36B-5786-4FB0-8501-F409EA6C4A3BQ36243814-B32A5B61-0859-4329-A4E4-8393A113FB3FQ36563103-BEC323CF-BD91-4E30-9948-816686DC7769Q37192952-2FE6DCB2-CD55-496D-B071-52070964D39AQ37210678-B1ED799E-869A-4A21-96F0-5DA74760B9F5Q37270778-AF744B80-68E2-450E-8628-2AF74CBB117AQ37341623-79000CCE-94E6-4F18-9A34-419C3B771999Q37601789-5BC9E680-9958-4697-ACDE-99BDAE03C10BQ37696024-4AF64C43-2E8A-4D3B-8102-860A50014B20Q37973611-BFACE100-995B-4970-9695-1FDBFD8803E0Q38199670-935C210F-8E92-4DA3-AFF9-726DC66084E7Q38223905-E2D58F6F-C78E-4F56-A5B3-444F25D3B42FQ39328856-FDCC14CD-B103-4737-BF0D-9BBB8F91A655Q41963193-78850B93-F869-4B5E-A943-32137C3381D5Q42023708-DED2F872-E6DB-478E-9EF3-188BACCAB064Q42512289-C850F47B-1452-4D31-9787-9F33BA24893EQ46178686-8252B651-3BEA-43DA-8A05-BDBDEC7DEF1EQ47920457-0F9CD021-E5EB-4008-85AA-435FD259BE7AQ48300577-A00A8496-3525-46A3-9C74-DD266BA7E46BQ48362193-C5FFA3D5-987D-48D7-913D-82BABF2FD867Q52665081-F3B5FA66-0C6A-4BE7-A0A2-E293EED7B174Q53410082-896BDCC2-27D7-4FD3-A80D-57FCE1036FD5
P2860
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Evidence for a role of the 5-H ...... animal model of Parkinsonism.
@en
type
label
Evidence for a role of the 5-H ...... animal model of Parkinsonism.
@en
prefLabel
Evidence for a role of the 5-H ...... animal model of Parkinsonism.
@en
P2860
P356
P1476
Evidence for a role of the 5-H ...... animal model of Parkinsonism.
@en
P2093
Per E Andren
Xiaoqun Zhang
P2860
P304
P356
10.1073/PNAS.0711839105
P407
P577
2008-02-06T00:00:00Z